DE69919995D1 - Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis - Google Patents
Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsisInfo
- Publication number
- DE69919995D1 DE69919995D1 DE69919995T DE69919995T DE69919995D1 DE 69919995 D1 DE69919995 D1 DE 69919995D1 DE 69919995 T DE69919995 T DE 69919995T DE 69919995 T DE69919995 T DE 69919995T DE 69919995 D1 DE69919995 D1 DE 69919995D1
- Authority
- DE
- Germany
- Prior art keywords
- enzephalopathy
- encephalothlipsis
- hypertensive
- consequence
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7228098 | 1998-03-20 | ||
| JP7228098 | 1998-03-20 | ||
| PCT/JP1999/001335 WO1999048522A1 (en) | 1998-03-20 | 1999-03-17 | Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69919995D1 true DE69919995D1 (de) | 2004-10-14 |
| DE69919995T2 DE69919995T2 (de) | 2005-09-22 |
Family
ID=13484725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69919995T Expired - Lifetime DE69919995T2 (de) | 1998-03-20 | 1999-03-17 | Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6342531B1 (de) |
| EP (1) | EP1064021B1 (de) |
| JP (1) | JP2002507579A (de) |
| KR (1) | KR20010041967A (de) |
| CN (1) | CN1301173A (de) |
| AR (1) | AR018784A1 (de) |
| AT (1) | ATE275420T1 (de) |
| AU (1) | AU2852699A (de) |
| BR (1) | BR9908948A (de) |
| CA (1) | CA2324566A1 (de) |
| DE (1) | DE69919995T2 (de) |
| ES (1) | ES2224613T3 (de) |
| HU (1) | HUP0101428A2 (de) |
| ID (1) | ID27507A (de) |
| MX (1) | MXPA00009188A (de) |
| MY (1) | MY133063A (de) |
| NO (1) | NO20004679L (de) |
| PL (1) | PL342970A1 (de) |
| WO (1) | WO1999048522A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7766300A (en) * | 1999-10-07 | 2001-05-10 | Novaneuron Inc. | Gene necessary for striatal function, uses thereof, and compounds for modulatingsame |
| AU2001292287A1 (en) | 2000-10-26 | 2002-05-06 | Senju Pharmaceutical Co. Ltd. | Drug composition comprising dipeptydyl aldehyde derivative |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0564552A1 (de) | 1990-12-28 | 1993-10-13 | Cortex Pharmaceuticals, Inc. | Verwendung von calpaininhibitoren zur hemmung und behandlung von neurodegeneration |
| DE69628050T2 (de) | 1995-10-25 | 2004-04-01 | Senju Pharmaceutical Co., Ltd. | Angiogenese Hemmer |
-
1999
- 1999-03-17 EP EP99909212A patent/EP1064021B1/de not_active Expired - Lifetime
- 1999-03-17 CA CA002324566A patent/CA2324566A1/en not_active Abandoned
- 1999-03-17 JP JP2000537569A patent/JP2002507579A/ja not_active Ceased
- 1999-03-17 CN CN99806167A patent/CN1301173A/zh active Pending
- 1999-03-17 ES ES99909212T patent/ES2224613T3/es not_active Expired - Lifetime
- 1999-03-17 DE DE69919995T patent/DE69919995T2/de not_active Expired - Lifetime
- 1999-03-17 AT AT99909212T patent/ATE275420T1/de not_active IP Right Cessation
- 1999-03-17 MX MXPA00009188A patent/MXPA00009188A/es unknown
- 1999-03-17 MY MYPI99000998A patent/MY133063A/en unknown
- 1999-03-17 HU HU0101428A patent/HUP0101428A2/hu unknown
- 1999-03-17 PL PL99342970A patent/PL342970A1/xx not_active Application Discontinuation
- 1999-03-17 AU AU28526/99A patent/AU2852699A/en not_active Abandoned
- 1999-03-17 BR BR9908948-3A patent/BR9908948A/pt not_active Application Discontinuation
- 1999-03-17 KR KR1020007010291A patent/KR20010041967A/ko not_active Application Discontinuation
- 1999-03-17 US US09/646,529 patent/US6342531B1/en not_active Expired - Fee Related
- 1999-03-17 WO PCT/JP1999/001335 patent/WO1999048522A1/en active IP Right Grant
- 1999-03-17 ID IDW20002104A patent/ID27507A/id unknown
- 1999-03-19 AR ARP990101215A patent/AR018784A1/es unknown
-
2000
- 2000-09-19 NO NO20004679A patent/NO20004679L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999048522A1 (en) | 1999-09-30 |
| DE69919995T2 (de) | 2005-09-22 |
| ATE275420T1 (de) | 2004-09-15 |
| ES2224613T3 (es) | 2005-03-01 |
| MY133063A (en) | 2007-10-31 |
| NO20004679L (no) | 2000-10-26 |
| EP1064021A1 (de) | 2001-01-03 |
| CN1301173A (zh) | 2001-06-27 |
| KR20010041967A (ko) | 2001-05-25 |
| PL342970A1 (en) | 2001-07-16 |
| CA2324566A1 (en) | 1999-09-30 |
| BR9908948A (pt) | 2000-11-21 |
| JP2002507579A (ja) | 2002-03-12 |
| ID27507A (id) | 2001-04-12 |
| NO20004679D0 (no) | 2000-09-19 |
| HUP0101428A2 (hu) | 2001-09-28 |
| US6342531B1 (en) | 2002-01-29 |
| AU2852699A (en) | 1999-10-18 |
| MXPA00009188A (es) | 2002-04-24 |
| EP1064021B1 (de) | 2004-09-08 |
| AR018784A1 (es) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60015392D1 (de) | Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen | |
| DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DE60108080D1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
| ATE330593T1 (de) | Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
| ATE271038T1 (de) | 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen | |
| DE50212701D1 (de) | Bestrahlungsanordnung zur behandlung von akne und aknenarben | |
| DE69934813D1 (de) | Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen | |
| DE69925488D1 (de) | Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen | |
| ATE246518T1 (de) | Egr-1 zur herstellung eines medikamentes zur behandlung von wunden | |
| DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien | |
| DE60001725D1 (de) | Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression | |
| DE60224004D1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| DE60305400D1 (de) | Anlage zur Behandlung von Produkten und dazugehörige Datenerfassungseinheit | |
| ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| DE69919995D1 (de) | Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis | |
| DE60223810D1 (de) | Organische nitrat-derivate zur behandlung von atherosklerose und vaskulären erkrankungen | |
| ATE234613T1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
| DE60233740D1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit | |
| DE10295506D2 (de) | Verfahren und Behandlung von Materialien biologischen Ursprungs und Kollagen-Elastin-Product | |
| DE69715878D1 (de) | Formulierung zur behandlung und/oder vorbeugung von dementia | |
| DE50012667D1 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen | |
| DE59904564D1 (de) | Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |